Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P80404 (
GABA transaminase
)
786
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The hypothesis that the brain GABA level increase which is induced by a sodium dipropyl acetate treatment arises either through inhibition of succinic semialdehyde dehydrogenase (SSADH), or through inhibition of
GABA transaminase
by succinic semialdehyde (SSA), has been considered. It appeared that in vivo brain GABA level increase cannot be attributed to SSADH inhibition, and that SSA is not a GABA precursor. It has been shown that SSA is neither in vivo nor in vitro a GABA-transaminase inhibitor.
4-hydroxybenzaldehyde
, a potent SSADH inhibitor did not increase GABA level at a dosage which induces a 99% inhibition of SSADH.
...
PMID:[Mechanism of action of an anticonvulsant, sodium dipropylacetate]. 645 31
Ether fraction of G. elata methanol extract significantly inhibited the recovery time and severity induced by pentylenetetrazole (PTZ) treatment. Pretreatment of ether fraction of G. elata methanol extract successfully prevented diminution of brain GABA level in subconvulsive dose of PTZ-treated rats.
4-Hydroxybenzaldehyde
, an analogue of p-hydroxybenzyl alcohol, showed an inhibitory effect on the
GABA transaminase
, and its inhibitory activity was higher than that of valproic acid, a known anticonvulsant. In the brain of PTZ-treated rats, brain lipid peroxidation was significantly increased, while it recovered to the control level after treatment with
4-hydroxybenzaldehyde
. It may be concluded that antioxidation and positive modulation of GABAergic neuromodulation of
4-hydroxybenzaldehyde
partially contribute to an antiepileptic and anticonvulsive activity of G. elata B1.
...
PMID:4-Hydroxybenzaldehyde from Gastrodia elata B1. is active in the antioxidation and GABAergic neuromodulation of the rat brain. 1102 74
The present study was designed to characterize the modulatory effects of the constituents of Gastrodia elata and their analogues on the GABAergic neurotransmission.
4-Hydroxybenzaldehyde
(1) and 4-hydroxy-3-methoxybenzaldehyde (4) inhibited potently the activity of
GABA transaminase
(IC(50) = 4.1 and 5.4 microg/ml, respectively), while the activity of another constituent, 4-hydroxybenzyl alcohol (2), was very weak. Further investigation with 10 analogues revealed a structure-activity correlation, suggesting that the aldehyde group and the hydroxy group at C-4 are necessary for the inhibitory effect on the enzyme activity. Some potent enzyme inhibitors were examined for the effect on the radioligands to the GABA(A) receptor complexes of rat cerebral cortices. Among them, the component 4 dose-dependently increased (20 - 30 %) the binding of [(3)H]flunitrazepam in the presence of GABA.
...
PMID:In vitro effects of hydroxybenzaldehydes from Gastrodia elata and their analogues on GABAergic neurotransmission, and a structure-activity correlation. 1174 32
4-Hydroxybenzaldehyde
(HBA) derivatives were examined as inhibitors for
GABA transaminase
(
GABA-T
) and succinic semialdehyde dehydrogenase (SSADH). Investigation of structure-activity relation revealed that a carbonyl group or an amino group as well as a hydroxy group at the para position of the benzene ring are important for both enzymes' inhibition. HBA was shown to give competitive inhibition of
GABA-T
with respect to alpha-ketoglutarate and competitive inhibition of SSADH. 4-Hydroxybenzylamine (HBM) also showed the competitive inhibition on
GABA-T
with respect to GABA. In conclusion, the inhibitory effects of HBA and HBM on both enzymes could result from the similarity between both molecules and the two enzymes' substrates in structure, as well as the conjugative effect of the benzene ring. This suggested that the presence of the benzene ring may be accepted by the active site of both enzymes, HBA and HBM may be considered as lead compounds to design novel
GABA-T
inhibitors.
...
PMID:Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. 1629 Jan 45
Previous study showed that
4-hydroxybenzaldehyde
is a competitive inhibitor of
GABA transaminase
. As a result, 4-acryloylphenol was synthesized as a
4-hydroxybenzaldehyde
analogue, and shown to inactivate potently the enzyme in a time-dependent manner. The inactivation was protected by alpha-ketoglutarate, indicating that it occurs at the active site of the enzyme. Beta-mercaptoethanol also prevented the enzyme from inactivation. The possible mechanism involving a Michael addition was proposed to rationalize the inactivation.
...
PMID:Inactivation of GABA transaminase by 4-acryloylphenol. 1669 Mar 13
Previously it was found that
4-hydroxybenzaldehyde
is a competitive inhibitor of
GABA transaminase
. Here 3-chloro-1-(4-hydroxyphenyl)propan-1-one (9), a
4-hydroxybenzaldehyde
analogue, was found to inactivate potently the enzyme in a time-dependent manner. alpha-Ketoglutarate prevented the enzyme from inactivation, suggesting that the inactivation occurs in its active site. Several experiments indicated that the inactivation is irreversible. This study provides a novel strategy for the design of more effective inhibitors.
...
PMID:Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. 1913 17